

Keep up with the latest information from *Diabetes* and other ADA titles via Facebook ([f](#)ADAJournals) and Twitter ([t](#)@ADA_Journals).

IN THIS ISSUE **3305**

PERSPECTIVES IN DIABETES

Sugar, uric acid, and the etiology of diabetes and obesity
 R.J. JOHNSON, T. NAKAGAWA, L.G. SANCHEZ-LOZADA, M. SHAFIU, S. SUNDARAM,
 M. LE, T. ISHIMOTO, Y.Y. SAUTIN, AND M.A. LANASPA 3307

Incretin action in the pancreas: potential promise, possible perils,
 and pathological pitfalls
 D.J. DRUCKER 3316

Novel hypothesis to explain why SGLT2 inhibitors inhibit only
 30–50% of filtered glucose load in humans
 M.A. ABDUL-GHANI, R.A. DEFONZO, AND L. NORTON 3324

COMMENTARIES

Diabetes and the heart: Is there objective evidence of a human
 diabetic cardiomyopathy?
 S.E. LITWIN 3329

Can ADAMTS13 lead us to the paradise of personalized medicine?
 P. ROSSING AND M. LAJER 3331

A new home for pancreatic islet transplants: the bone marrow
 A. PILEGGI AND C. RICORDI 3333

How sweet it is: intestinal sweet taste receptors in type 2 diabetes
 J.R. GREENFIELD AND D.J. CHISHOLM 3336

Genetic dissection of diabetes: facing the giant
 D. MEYRE AND G. PARE 3338

METHODOLOGY REVIEW

Assessing the human gut microbiota in metabolic diseases
 F. KARLSSON, V. TREMAROLI, J. NIELSEN, AND F. BÄCKHED 3341

METABOLISM

Skeletal muscle triacylglycerol hydrolysis does not influence
 metabolic complications of obesity
 M.T. SITNICK, M.K. BASANTANI, L. CAI, G. SCHOISWOHL, C.F. YAZBECK,
 G. DISTEFANO, V. RITOV, J.P. DELANY, R. SCHREIBER, D.B. STOLZ, N.P. GARDNER,
 P.C. KIENESBERGER, T. PULINILKUNNIL, R. ZECHNER, B.H. GOODPASTER,
 P. COEN, AND E.E. KERSHAW 3350

Remodeling the integration of lipid metabolism between liver
 and adipose tissue by dietary methionine restriction in rats
 B.E. HASEK, A. BOUDREAU, J. SHIN, D. FENG, M. HULVER, N.T. VAN, A. LAQUE,
 L.K. STEWART, K.P. STONE, D. WANDERS, S. GHOSH, J.E. PESSIN,
 AND T.W. GETTYS 3362

Blunted refeeding response and increased locomotor activity
 in mice lacking FoxO1 in synapsin-*cre*-expressing neurons
 H. REN, L. PLUM-MORSCHER, R. GUTIERREZ-JUAREZ, T.Y. LU, J.Y. KIM-MULLER,
 G. HEINRICH, S.L. WARDLAW, R. SILVER, AND D. ACCILI 3373

Dissociation of intestinal and hepatic activities of FXR and LXRs
 supports metabolic effects of terminal ileum interposition in
 rodents
 A. MENCARELLI, B. RENGA, C. D'AMORE, C. SANTORELLI, L. GRAZIOSI, A. BRUNO,
 M.C. MONTE, E. DISTRUTTI, S. CIPRIANI, A. DONINI, AND S. FIORUCCI 3384

Interferon regulatory factor 4 regulates obesity-induced
 inflammation through regulation of adipose tissue macrophage
 polarization
 J. EGUCHI, X. KONG, M. TENTA, X. WANG, S. KANG, AND E.D. ROSEN 3394

Sirt3 regulates metabolic flexibility of skeletal muscle through
 reversible enzymatic deacetylation
 E. JING, B.T. O'NEILL, M.J. RARDIN, A. KLEINRIDERS, O.R. ILKEYEVA,
 S. USSAR, J.R. BAIN, K.Y. LEE, E.M. VERDIN, C.B. NEWGARD, B.W. GIBSON,
 AND C.R. KAHN 3404

Oxytocin reduces reward-driven food intake in humans
 V. OTT, G. FINLAYSON, H. LEHNERT, B. HEITMANN, M. HEINRICHS, J. BORN,
 AND M. HALLSCHMID 3418

Mitochondrial substrate availability and its role in lipid-induced
 insulin resistance and proinflammatory signaling in skeletal muscle
 C. LIPINA, K. MACRAE, T. SUHM, C. WEIGERT, A. BLACHNIO-ZABIELSKA,
 M. BARANOWSKI, J. GORSKI, K. BURGESS, AND H.S. HUNDAL 3426

SIGNAL TRANSDUCTION

Impairments in site-specific AS160 phosphorylation and effects of
 exercise training
 L.A. CONSTITT, J. VAN METER, C.A. NEWTON, D.N. COLLIER, M.S. DAR,
 J.F.P. WOJTASZEWSKI, J.T. TREEBAK, C.J. TANNER, AND J.A. HOUMARD 3437

ISLET STUDIES

Glucokinase activation ameliorates ER stress-induced apoptosis
 in pancreatic β -cells
 J. SHIRAKAWA, Y. TOGASHI, E. SAKAMOTO, M. KAJI, K. TAJIMA, K. ORIME, H. INOUE,
 N. KUBOTA, T. KADOWAKI, AND Y. TERAUCHI 3448

PDX1 in ducts is not required for postnatal formation of β -cells
 but is necessary for their subsequent maturation
 L. GUO, A. INADA, C. AGUAYO-MAZZUCATO, J. HOLLISTER-LOCK, Y. FUJITANI,
 G.C. WEIR, C.V.E. WRIGHT, A. SHARMA, AND S. BONNER-WEIR 3459

Consequences of exposure to light at night on the pancreatic islet
 circadian clock and function in rats
 J. QIAN, G.D. BLOCK, C.S. COLWELL, AND A.V. MATVEYENKO 3469

Mouse muscle as an ectopic permissive site for human pancreatic
 development
 C. CAPITO, M.-T. SIMON, V. AIELLO, A. CLARK, Y. AIGRAIN, P. RAVASSARD,
 AND R. SCHARFMANN 3479

Loss of prohibitin induces mitochondrial damages altering β -cell
 function and survival and is responsible for gradual diabetes
 development
 S. SUPALE, F. THOREL, C. MERKWIRTH, A. GJINOVCI, P.L. HERRERA, L. SCORRANO,
 P. MEDA, T. LANGER, AND P. MAECHLER 3488

Resveratrol prevents β -cell dedifferentiation in nonhuman
 primates given a high-fat/high-sugar diet
 J.L. FIORI, Y.-K. SHIN, W. KIM, S.M. KRZYSIK-WALKER, I. GONZÁLEZ-MARISCAL,
 O.D. CARLSON, M. SANGHVI, R. MOADDEL, K. FARHANG, S.K. GADKAREE,
 M.E. DOYLE, K.J. PEARSON, J.A. MATTISON, R. DE CABO, AND J.M. EGAN 3500

Development of the human pancreas from foregut to endocrine
 commitment
 R.E. JENNINGS, A.A. BERRY, R. KIRKWOOD-WILSON, N.A. ROBERTS, T. HEARN,
 R.J. SALISBURY, J. BLAYLOCK, K. PIPER HANLEY, AND N.A. HANLEY 3514

IMMUNOLOGY AND TRANSPLANTATION

Autologous pancreatic islet transplantation in human bone marrow
 P. MAFFI, G. BALZANO, M. PONZONI, R. NANO, V. SORDI, R. MELZI, A. MERCALLI,
 M. SCAVINI, A. ESPOSITO, J. PECCATORI, E. CANTARELLI, C. MESSINA, M. BERNARDI,
 A. DEL MASCHIO, C. STAUDACHER, C. DOGLIONI, F. CICERI, A. SECCHI, AND L. PIEMONTE 3523

PATHOPHYSIOLOGY

Disordered control of intestinal sweet taste receptor expression
 and glucose absorption in type 2 diabetes
 R.L. YOUNG, B. CHIA, N.J. ISAACS, J. MA, J. KHOO, T. WU, M. HOROWITZ, AND C.K. RAYNER 3532

More than 20 years of registration of type 1 diabetes in Sardinian
 children: temporal variations of incidence with age, period
 of diagnosis, and year of birth
 G. BRUNO, M. MAULE, A. BIGGERI, A. LEDDA, C. MANNU, F. MERLETTI, M. SONGINI,
 AND THE SARDINIAN GROUP FOR DIABETES EPIDEMIOLOGY 3542

Combination pravastatin and valsartan treatment has additive
 beneficial effects to simultaneously improve both metabolic
 and cardiovascular phenotypes beyond that of monotherapy
 with either drug in patients with primary hypercholesterolemia
 K.K. KOH, S. LIM, H. CHOI, Y. LEE, S.H. HAN, K. LEE, P.C. OH, I. SAKUMA, E.K. SHIN,
 AND M.J. QUON 3547

COMPLICATIONS

Insulin receptor phosphorylation by endogenous insulin or the
 insulin analog AspB10 promotes mammary tumor growth
 independent of the IGF-I receptor
 E.J. GALLAGHER, N. ALIKHANI, A. TOBIN-HESS, J. BLANK, N.J. BUFFIN, Z. ZELENKO,
 N. TENNAGELS, U. WERNER, AND D. LEROITH 3553

Effects of prior intensive versus conventional therapy and history of glycemia on cardiac function in type 1 diabetes in the DCCT/EDIC
S.M. GENUTH, J.-Y.C. BACKLUND, M. BAYLESS, D.A. BLUEMKE, P.A. CLEARY,
J. CRANDALL, J.M. LACHIN, J.A.C. LIMA, C. MIAO, AND E.B. TURKBAY, FOR THE
DCCT/EDIC RESEARCH GROUP 3561

Severe hypoglycemia-induced lethal cardiac arrhythmias
are mediated by sympathoadrenal activation
C.M. RENO, D. DAPHNA-IKEN, Y.S. CHEN, J. VANDERWEELE, K. JETHI,
AND S.J. FISHER 3570

PHARMACOLOGY AND THERAPEUTICS

Ebselen treatment prevents islet apoptosis, maintains intranuclear Pdx-1
and MafA levels, and preserves β -cell mass and function in ZDF rats
J. MAHADEVAN, S. PARAZZOLI, E. OSEID, A.V. HERTZEL, D.A. BERNLOHR,
S.N. VALLERIE, C.-Q. LIU, M. LOPEZ, J.S. HARMON, AND R.P. ROBERTSON 3582

GENETICS/GENOMES/PROTEOMICS/METABOLOMICS

Mendelian randomization studies do not support a causal role
for reduced circulating adiponectin levels in insulin resistance
and type 2 diabetes
H. YAGHOOTKAR, C. LAMINA, R.A. SCOTT, Z. DASTANI, M.-F. HIVERT, L.L. WARREN,
A. STANČÁKOVÁ, S.G. BUXBAUM, L.-P. LYYTIKÄINEN, P. HENNEMAN, Y. WU,
C.Y.Y. CHEUNG, J.S. PANKOW, A.U. JACKSON, S. GUSTAFSSON, J.H. ZHAO,
C.M. BALLANTYNE, W. XIE, R.N. BERGMAN, M. BOEHNKE, F. EL BOUAZZAOU,
F.S. COLLINS, S.H. DUNN, J. DUPUIS, N.G. FOROUI, C. GILLSON, A.T. HATTERSLEY,
J. HONG, M. KÄHÖNEN, J. KUUSISTO, L. KEDENKO, F. KRONENBERG, A. DORIA,
T.L. ASSIMES, E. FERRANNINI, T. HANSEN, K. HAO, H. HÄRING, J.W. KNOWLES,
C.M. LINDGREN, J.J. NOLAN, J. PAANANEN, O. PEDERSEN, T. QUERTERMOUS,
U. SMITH, THE GENESIS CONSORTIUM, THE RISC CONSORTIUM, T. LEHTIMÄKI,
C.-T. LIU, R.J.F. LOOS, M.I. MCCARTHY, A.D. MORRIS, R.S. VASAN, T.D. SPECTOR,
T.M. TESLOVICH, J. TUOMILEHTO, K.W. VAN DIJK, J.S. VIHKARI, N. ZHU,
C. LANGENBERG, E. INGELSSON, R.K. SEMPLE, A.R. SINAIKO, C.N.A. PALMER,
M. WALKER, K.S.L. LAM, B. PAULWEBER, K.L. MOHLKE, C. VAN DUJN,
O.T. RAITAKARI, A. BIDULESCU, N.J. WAREHAM, M. LAAKSO, D.M. WATERWORTH,
D.A. LAWLOR, J.B. MEIGS, J.B. RICHARDS, AND T.M. FRAYLING 3589

ADAMTS13 predicts renal and cardiovascular events in type 2
diabetic patients and response to therapy
E. RURALI, M. NORIS, A. CHIANCA, R. DONADELLI, F. BANTERLA, M. GALBUSERA,
G. GHERARDI, S. GASTOLDI, A. PARVANOVA, I. ILIEV, A. BOSSI, C. HAEFLIGER,
R. TREVISAN, G. REMUZZI, AND P. RUGGENENTI, FOR THE BENEDICT STUDY GROUP 3599

Genetic risk score of 46 type 2 diabetes risk variants associates
with changes in plasma glucose and estimates of pancreatic β -cell
function over 5 years of follow-up
E.A. ANDERSSON, K.H. ALLIN, C.H. SANDHOLT, A. BORGLYKKE, C.J. LAU,
R. RIBEL-MADSEN, T. SPARSØ, J.M. JUSTESEN, M.N. HARDER, M.E. JØRGENSEN,
T. JØRGENSEN, T. HANSEN, AND O. PEDERSEN 3610

Association of ketone body levels with hyperglycemia and type 2
diabetes in 9,398 finnish men
Y. MAHENDRAN, J. VANGIPURAPU, H. CEDERBERG, A. STANČÁKOVÁ, J. PIHLAJAMÄKI,
P. SOININEN, A.J. KANGAS, J. PAANANEN, M. CIVELEK, N.K. SALEEM, P. PAJUKANTA,
A.J. LUSIS, L.L. BONNYCASTLE, M.A. MORKEN, F.S. COLLINS, K.L. MOHLKE,
M. BOEHNKE, M. ALA-KORPELA, J. KUUSISTO, AND M. LAAKSO 3618

Genetic modifiers of cystic fibrosis-related diabetes
S.M. BLACKMAN, C.W. COMMANDER, C. WATSON, K.M. ARCARA, L.J. STRUG,
J.R. STONEBRAKER, F.A. WRIGHT, J.M. ROMMENS, L. SUN, R.G. PACE,
S.A. NORRIS, P.R. DURIE, M.L. DRUMM, M.R. KNOWLES, AND G.R. CUTTING 3627

Patterns of β -cell autoantibody appearance and genetic
associations during the first years of life
J. ILOINEN, A. HAMMAIS, A.-P. LAINE, J. LEMPAINEN, O. VAARALA, R. VEIJOLA,
O. SIMELL, AND M. KNIP 3636

ERRATUM

Identification of *HKDC1* and *BACE2* as genes influencing
glycemic traits during pregnancy through genome-wide
association studies. *Diabetes* 2013;62:3282–3291
M.G. HAYES, M. URBANEK, M.-F. HIVERT, L.L. ARMSTRONG, J. MORRISON,
C. GUO, L.P. LOWE, D.A. SCHEFTNER, A. PLUZHNIKOV, D.M. LEVINE,
C.P. MCHUGH, C.M. ACKERMAN, L. BOUCHARD, D. BRISSON, B.T. LAYDEN,
D. MIREL, K.F. DOHENY, M.V. LEYA, R.N. LOWN-HECHT, A.R. DYER,
B.E. METZGER, T.E. REDDY, N.J. COX, AND W.L. LOWE JR., FOR THE HAPO
STUDY COOPERATIVE RESEARCH GROUP 3641

ISSUES AND EVENTS

DIABETES DIGESTS

ONLINE LETTERS TO THE EDITOR

Comment on: Butler et al. Marked expansion of exocrine
and endocrine pancreas with incretin therapy in humans
with increased exocrine pancreas dysplasia and the potential
for glucagon-producing neuroendocrine tumors.
Diabetes 2013;62:2595–2604
R.J. HEINE, H. FU, D.M. KENDALL, AND D.E. MOLLER e16

Comment on: Butler et al. Marked expansion of exocrine
and endocrine pancreas with incretin therapy in humans
with increased exocrine pancreas dysplasia and the potential
for glucagon-producing neuroendocrine tumors.
Diabetes 2013;62:2595–2604
S.S. ENGEL, G.T. GOLM, AND B. LAURING e18

Response to comments on: Butler et al. Marked expansion
of exocrine and endocrine pancreas with incretin therapy
in humans with increased exocrine pancreas dysplasia
and the potential for glucagon-producing neuroendocrine
tumors. *Diabetes* 2013;62:2595–2604
A.E. BUTLER, M. CAMPBELL-THOMPSON, T. GURLO, D.W. DAWSON, M. ATKINSON,
AND P.C. BUTLER e19

Comment on: Tessari et al. Roles of insulin, age, and asymmetric
dimethylarginine on nitric oxide synthesis in vivo.
Diabetes 2013;62:2699–2708
O. KRUSZELNICKA, T. RAKOWSKI, AND A. SURDACKI e23

Response to comment on: Tessari et al. Roles of insulin, age,
and asymmetric dimethylarginine on nitric oxide synthesis in vivo.
Diabetes 2013;62:2699–2708
P. TESSARI e24

Comment on: Selvin et al. sRAGE and risk of diabetes,
cardiovascular disease, and death. *Diabetes* 2013;62:2116–2121
C.G. SCHALKWJK AND C.D.A. STEHOUEWER e25

Comment on: Selvin et al. sRAGE and risk of diabetes,
cardiovascular disease, and death. *Diabetes* 2013;62:2116–2121
S.-I. YAMAGISHI e26

Response to comments on: Selvin et al. sRAGE and risk of
diabetes, cardiovascular disease, and death.
Diabetes 2013;62:2116–2121
E. SELVIN, J. CORESH, AND M.K. HALUSHKA e27

Cover: The image is an immunofluorescent micrograph of murine skeletal muscle lacking adipose triglyceride lipase (ATGL), the rate-limiting enzyme in triacylglycerol hydrolysis, demonstrating massive fiber type-specific intramyocellular lipid accumulation. Skeletal muscle derived from skeletal muscle-specific ATGL knockout (SMAKO) mice were stained with LipidTOX Red for neutral lipids (red), Tom20 for mitochondria (green), and phalloidin for F-actin (blue). Image courtesy of Erin E. Kershaw, MD, and Donna B. Stolz, PhD, coauthors of “Skeletal muscle triacylglycerol hydrolysis does not influence metabolic complications of obesity” found in this issue of *Diabetes* (p. 3350).